Slide 1: FY 2018 Results
FY 2018 Results DIASORIN SPA March 14, 2019
Slide 2: Disclaimer
Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela
Slide 3: Highlights
Highlights PLACEMENTS FY’18 @ Dec 31, 2018 FY’18 @ curr @ CER LIAISON XL +483 4,001 REVENUES €/mln 669.2 (*) +5.0% +7.7% LIAISON -32 3,848 CLIA EX VIT D +8.2% +10.4% VIT D -7.0% -3.7% TOTAL +451 7,849 ELISA TESTS +12.7% +15.4% IMMUNO MOLECULAR TESTS (**) +4.0% +8.6% BUSINESS DEVELOPMENT INSTRUMENTS
Slide 4: Q4 and FY 2018 revenues growth
Q4 and FY 2018 revenues growth Q4’18 vs. Q4’17 FY’18 vs. FY’17 Q4’18 vs. Q4’17 FY’18 vs. FY’17 Total Group revenues @ curr +3.8% +5.0% EUROPE & AFRICA +5.1% +11.7% @ CER +3.6% +7.7% CLIA ex Vit D sales growth and consolidation of Siemens’ Germany +1.8% +16.5% ELISA business CLIA sales increase (main
Slide 5: FY 2018 revenues breakdown
FY 2018 revenues breakdown by geography by technology Instruments & other revenues FY’17 (*) FY’17 (*) U.S. and Canada 11.8% 30.6% Molecular diagnostic tests (**) Europe & Africa 8.5% 43.6% CLIA tests 66.4% ELISA tests 13.3% Asia Pacific 18.4% Latin America 7.4% FY’18 FY’18 Instruments & other reven
Slide 6: Installed base expansion
Installed base expansion 7,398 7,501 7,623 7,734 7,849 +483 3,518 +116 3,634 +123 3,757 +128 3,885 +116 4,001 LAS 3,880 -13 3,867 -1 3,866 -17 3,849 -1 3,848 -32 @ Dec 31, 2017 @ March 31, 2018 @ June 30, 2018 @ Sept 30, 2018 @ Dec 31, 2018 FY 2018 Results 6
Slide 7: Q4 and FY 2018 profitability profile
Q4 and FY 2018 profitability profile Q4’17 Q4’18 Change % FY’17 FY’18 Change % EBITDA (€/MLN) 55.8 68.2 +22.4% 237.9 255.4 +7.3% @ CER +23.1% +11.2% EBITDA MARGIN 33.0% 38.9% +592 bps 37.3% 38.2% +84 bps @ CER 39.3% +624 bps 38.5% +118 bps FY’18 EBITDA upward as result of: • Increase in Gross Profit
Slide 8: FY 2019 Company Guidance
FY 2019 Company Guidance 8
Slide 9: FY 2019 company guidance @ CER compared to 2018
FY 2019 company guidance @ CER (*) compared to 2018 Revenues Growth between +5.0% and + 8.0% EBITDA margin Comparable to 2018 EBITDA margin result (*) 2018 €/US$ exchange rate: 1.18 FY 2018 Results 9
Slide 10: Investor Day June 11, Turin
“Investor Day June 11" Turin
Slide 11: Financial schemes
Financial schemes 11
Slide 12: Income Statement
Income Statement FY Change Data in € million 2017 2018 amount % Net revenues 637.5 669.2 +31.7 +5.0% Gross profit 431.9 455.8 +23.9 +5.5% Gross Margin 67.7% 68.1% +36 bps S&M (123.2) (133.1) -9.9 +8.0% R&D (43.6) (45.1) -1.5 +3.3% G&A (64.7) (67.2) -2.5 +3.9% Total operating expenses (231.5) (245.4)
Slide 13: Balance Sheet
Balance Sheet Data in € million 12/31/17 12/31/18 Change Goodwill and intangibles assets 344.4 373.1 +28.7 Property, plant and equipment 92.3 95.0 +2.6 Other non-current assets 23.8 23.0 -0.8 Net working capital 190.7 201.0 +10.3 Assets held for sale 4.0 - -4.0 Other non-current liabilities (62.5) (
Slide 14: Cash Flow Statement
Cash Flow Statement FY Data in € million Change 2017 2018 Cash and cash equivalents at the beginning of the period 130.5 159.3 +28.9 Operating activities 167.4 209.9 +42.4 Investing activities (38.0) (49.4) -11.4 Financing activities (55.6) (215.2) -159.7 Acquisitions of companies and business opera
Slide 15: DiaSorin
DiaSorin jt our new website www.diasoringroup.com